HomeCompareWGNR vs PFE

WGNR vs PFE: Dividend Comparison 2026

WGNR yields 14184.40% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 WGNR wins by $1741245461664930048.00M in total portfolio value
10 years
WGNR
WGNR
● Live price
14184.40%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1741245461664930048.00M
Annual income
$1,717,427,461,345,424,000,000,000.00
Full WGNR calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — WGNR vs PFE

📍 WGNR pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodWGNRPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, WGNR + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
WGNR pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

WGNR
Annual income on $10K today (after 15% tax)
$1,205,673.76/yr
After 10yr DRIP, annual income (after tax)
$1,459,813,342,143,610,500,000,000.00/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, WGNR beats the other by $1,459,813,342,143,610,500,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of WGNR + PFE for your $10,000?

WGNR: 50%PFE: 50%
100% PFE50/50100% WGNR
Portfolio after 10yr
$870622730832465024.00M
Annual income
$858,713,730,672,712,000,000,000.00/yr
Blended yield
98.63%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

WGNR
No analyst data
Altman Z
-288.0
Piotroski
4/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

WGNR buys
0
PFE buys
0
No recent congressional trades found for WGNR or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricWGNRPFE
Forward yield14184.40%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$1741245461664930048.00M$49.6K
Annual income after 10y$1,717,427,461,345,424,000,000,000.00$26,258.71
Total dividends collected$1739668430966621440.00M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: WGNR vs PFE ($10,000, DRIP)

YearWGNR PortfolioWGNR Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$1,429,140$1,418,439.72$9,153$693.39+$1.42MWGNR
2$190,982,313$189,453,134.00$8,593$849.25+$190.97MWGNR
3$23,865,535,334$23,661,184,258.31$8,336$1,066.78+$23865.53MWGNR
4$2,788,853,260,935$2,763,317,138,127.58$8,437$1,384.80+$2788853.25MWGNR
5$304,771,704,176,462$301,787,631,187,262.06$9,013$1,875.40+$304771704.17MWGNR
6$31,148,518,911,483,350$30,822,413,188,014,540.00$10,306$2,680.72+$31148518911.47MWGNR
7$2,977,381,874,110,252,500$2,944,052,958,874,965,500.00$12,820$4,101.38+$2977381874110.24MWGNR
8$266,187,755,143,456,800,000$263,001,956,538,158,780,000.00$17,673$6,826.70+$266187755143456.75MWGNR
9$22,259,813,382,715,685,000,000$21,974,992,484,712,187,000,000.00$27,543$12,591.86+$22259813382715684.00MWGNR
10$1,741,245,461,664,930,200,000,000$1,717,427,461,345,424,000,000,000.00$49,560$26,258.71+$1741245461664930048.00MWGNR

WGNR vs PFE: Complete Analysis 2026

WGNRStock

Wegener Corporation, through its subsidiary, Wegener Communications, Inc., designs, manufactures, and distributes satellite communications electronics equipment in the United States and internationally. The company offers iPump media servers, which receives and stores television, radio, and other digital files from broadcast, cable, and business network operations; Compel Network Control and Compel Conditional Access for dynamic command, monitoring, and addressing multi-site video, audio, and data networks; and Nielsen Media Research products, such as NAVE IIc and SpoTTrac encoders, which are used to encode Nielsen Media Research identification tags into media for Nielsen program ratings, as well as MediaPlan network control and content management products, which provides digital asset management in an end-to-end multi-site environment. It also provides Unity satellite media receivers, including Unity 552 for private and business television networks; Unity 4600, a digital satellite receiver that is used primarily by program originators to distribute analog and digital programming; and Unity 202 audio receiver for business music providers. In addition, the company offers digital television digital stream processors for cable and telecom headends allowing them to integrate local off-air high definition broadcast television channels and digital programs, and insert them onto their networks; uplink equipment for video and audio distribution; and customized products. It serves business and private networks, broadcast television and program originators, and radio broadcasters through direct sales force, sales representatives, value added resellers, integrators, and independent distributors. The company was founded in 1977 and is headquartered in Johns Creek, Georgia. As of December 29, 2017, Wegener Corporation operates as a subsidiary of Novra Technologies Inc.

Full WGNR Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this WGNR vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

WGNR vs SCHDWGNR vs JEPIWGNR vs OWGNR vs KOWGNR vs MAINWGNR vs JNJWGNR vs MRKWGNR vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.